drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.
|Published (Last):||14 February 2017|
|PDF File Size:||15.76 Mb|
|ePub File Size:||2.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
A short alpha-phase is followed by a beta-phase half-life of 9—11 hours ; once daily dosing is adequate.
According to the manufacturer, drugs that may lead to reductions in caspofungin concentrations include carbamazepine. If a breast-feeding infant experiences an adverse effect related to a maternally ingested or administered drug, health care providers are encouraged to report the adverse effect to the FDA. However, site of infection, local susceptibility patterns, and specific microbial susceptibility should be assessed before choosing an alternative agent.
Oral antifungal agents e. There is little excretion or biotransformation during the first insegt hours post-infusion. Limited data are available. A mg loading dose has not been studied with this indication.
In addition, some Candida sp. If the mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg.
Because of its unique mechanism of action, cross-resistance with amphotericin B and the azoles is not expected.
Caspofungin does not interact substantially with the cytochrome P enzyme system, but does undergo significant hepatic metabolism.
These mutations are associated with higher MICs and breakthrough infection. Visually inspect prepared infusions for particulate matter and discoloration prior to administration. Remove peritoneal dialysis catheter. Coadministration of caspofungin with CYP enzyme inducers, such as the rifamycins, results in reduced caspofungin blood concentrations. For the treatment of intraabdominal candidiasis.
Metabolism occurs by hydrolysis and N-acetylation. Recommended as an alternative therapy in patients unable to tolerate oral therapy or those who are refractory to fluconazole. Resistance to caspofungin resulting in clinical failures has been observed with Candida and Aspergillus sp.
Caspofungin Acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for: Clinical practice guidelines suggest caspofungin as salvage therapy. Treat for at least 2 weeks followed by fluconazole for 6 to 12 months for osteomyelitis or 4 weeks for infectious arthritis.
Administering inducers of hepatic cytochrome P, such as nevirapine, concurrently with canidas may reduce the plasma concentrations of caspofungin.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi – Fresenius Kabi USA
It is not known how caspofungin drug clearance is induced. Administering inducers of hepatic cytochrome P, such as fosphenytoin, concurrently with caspofungin may reduce the plasma concentrations of caspofungin. Anaphylaxis has been reported. No data are available. For the treatment of Aspergillus cardiovascular system infections in patients who are refractory to or intolerant of other antifungal therapies. Neonates and Infants 1 to 2 months.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi
After surgical replacement of an infected valve, consider lifelong antifungal therapy. The manufacturer recommends against the concomitant use of caspofungin with cyclosporine unless the potential benefit outweighs the risk.
No adjustment in the loading dose is needed. Please review the latest applicable package insert for additional information and possible updates. Patients found to have a fungal infection should be treated for a minimum of 14 days; treatment should continue for at least 7 days after both neutropenia and clinical symptoms are resolved.
If hypokalemia occurs or persists, consider reducing the dichlorphenamide dose or discontinuing dichlorphenamide therapy. For the treatment of Candida pneumonia and pleural space infections.